Maryland company Orgenesis (ORGS) is developing a proprietary therapeutic platform that transforms adult liver cells into insulin-generating cells to provide patients with independent insulin production. Earlier this year, Orgenesis entered into a partnership with HekaBio K.K. to conduct clinical trials in Japan. The company appears to be moving into licensing the technology to other companies for further development.
Family or personal history. Your risk increases if you have prediabetes — a precursor to type 2 diabetes — or if a close family member, such as a parent or sibling, has type 2 diabetes. You're also at greater risk if you had gestational diabetes during a previous pregnancy, if you delivered a very large baby or if you had an unexplained stillbirth.